LAGUNA HILLS, Calif., July 7, 2026
PreludeDx™, a leader in precision diagnostics for early-stage breast cancer, has announced a strategic collaboration with Learn Look Locate, a global breast cancer education platform, to expand patient education surrounding ductal carcinoma in situ (DCIS) and support more informed treatment decision-making. The collaboration introduces a comprehensive patient-centered educational resource designed to help women newly diagnosed with DCIS better understand their individual recurrence risk, the potential role of radiation therapy, and how DCISionRT®, PreludeDx’s clinically validated molecular diagnostic test, can guide personalized treatment discussions. As precision medicine continues transforming oncology care, the initiative reflects a shared commitment to empowering patients with scientifically accurate, accessible information that supports shared decision-making between patients and healthcare professionals while encouraging more personalized approaches to breast cancer management.
New Educational Resource Supports Personalized Breast Cancer Care
The collaboration centers on the launch of “Do I Need Radiation If I Have DCIS? A Complete, Patient-Centered Guide to Making the Right Decision for You,” an educational resource developed to simplify complex clinical concepts for patients facing treatment decisions following a DCIS diagnosis. The guide explains the biology of ductal carcinoma in situ, recurrence risk assessment, treatment following lumpectomy, and the role of radiation therapy while introducing DCISionRT®, PreludeDx’s genomic assay that provides individualized information regarding 10-year recurrence risk and the potential benefit of adjuvant radiation therapy.
By translating clinical evidence into patient-friendly language, the resource aims to help women better understand their diagnosis, prepare meaningful questions for their physicians, and participate more confidently in treatment planning. The initiative highlights the growing importance of patient education as an integral component of precision oncology, ensuring that molecular diagnostic information can be effectively incorporated into clinical conversations and individualized care planning.
Collaboration Advances Precision Oncology Awareness
Advertisement
DCISionRT® has become an increasingly important precision medicine tool by combining molecular biomarkers with clinicopathologic factors to provide individualized recurrence risk assessment and predict the likelihood of benefiting from radiation therapy after breast-conserving surgery. Through the collaboration with Learn Look Locate, PreludeDx aims to broaden awareness of personalized treatment strategies while supporting women during one of the most challenging stages of the breast cancer journey. The educational initiative emphasizes key topics including how recurrence risk is evaluated, why treatment recommendations differ among patients, how DCISionRT® contributes to personalized decision-making, and which questions patients should discuss with their care teams before selecting a treatment approach.
The collaboration reflects the continuing evolution of precision oncology beyond laboratory diagnostics by integrating genomic testing with patient-centered education, helping improve health literacy, strengthen physician-patient communication, and support evidence-based treatment decisions. As personalized medicine becomes increasingly central to breast cancer care, initiatives that combine innovative molecular diagnostics with accessible educational resources are expected to play an increasingly important role in improving patient engagement, optimizing clinical outcomes, and advancing individualized treatment strategies for women diagnosed with ductal carcinoma in situ (DCIS).
Source: PreludeDx press release
